Relypsa (RLYP) Getting Somewhat Positive Media Coverage, Accern Reports

Headlines about Relypsa (NASDAQ:RLYP) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Relypsa earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.7568709020084 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

COPYRIGHT VIOLATION NOTICE: “Relypsa (RLYP) Getting Somewhat Positive Media Coverage, Accern Reports” was posted by Week Herald and is the property of of Week Herald. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://weekherald.com/2017/09/17/relypsa-rlyp-receiving-somewhat-favorable-media-coverage-report-finds.html.

About Relypsa

Relypsa, Inc is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company’s technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address.

Insider Buying and Selling by Quarter for Relypsa (NASDAQ:RLYP)

Receive News & Ratings for Relypsa Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply